Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 592316 | ISIN: US0551831078 | Ticker-Symbol:
1-Jahres-Chart
BAB INC Chart 1 Jahr
5-Tage-Chart
BAB INC 5-Tage-Chart
GlobeNewswire (Europe)
168 Leser
Artikel bewerten:
(1)

BAB, Inc. Reports Results for 3rd Quarter FY 2024

Finanznachrichten News

DEERFIELD, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- BAB, Inc. (OTCQB: BABB), announced its financial results for the third quarter ended August 31, 2024.

For the quarter ended August 31, 2024 BAB had revenues of $872,000 and net income of $160,000, or $0.02 per share earnings, versus revenues of $937,000 and net income of $168,000, or a $0.02 per share, for the same quarter last year. Royalty revenue increased for the third quarter 2024 compared to third quarter 2023. Franchise fee revenue and License fee and other income and Marketing Fund revenue decreased in the third quarter ended August 31, 2024 compared to same quarter 2023.

For the nine months ended August 31, 2024, revenues were $2,591,000 and net income was $405,000, or $0.06 per share, versus revenues of $2,547,000 and net income of $330,000, or $0.05 per share for the same period in 2023. Royalty revenue, franchise fee revenue, and License fee and other income increased for the nine months ended August 31, 2024 compared to same period 2023. Marketing Fund revenue decreased for the nine months ended August 31, 2024 compared to same period 2023.

Total operating expenses for the quarter ended August 31, 2024, were $667,000, versus $718,000, in 2023. The change in operating expenses for the quarter was primarily due to a decrease in marketing fund expenses of $52,000, a decrease in occupancy expense of $5,000, and a $2,000 decrease each in advertising and promotion and travel, offset by an increase in payroll and payroll related expenses of $3,000, and increase of $3,000 in professional service fees and an increase in employee benefits of $5,000. Total operating expenses for the nine months ended August 31, 2024 were $2,077,000 versus $2,107,000 for August 31, 2023 with a decrease in marketing expenses of $11,000, a decrease in payroll and payroll related expenses of $13,000, a decrease in occupancy expense of $11,000 and advertising and promotion expense of $10,000 in 2024 compared to 2023, offset by an increase in professional fees of $14,000 and an increase of $4,000 in general expenses for the nine months in 2024 compared to 2023.

BAB, Inc. franchises and licenses Big Apple Bagels®, My Favorite Muffin®, SweetDuet® frozen yogurt and Brewster's® Coffee. The Company's stock is traded on the OTCQB under the symbol BABB and its website can be visited at www.babcorp.com.

Certain statements in this press release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "estimate," "project," "intend," "expect," "should," "would," "believe" and similar expressions and all statements which are not historical facts are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the company's actual results, performance (financial or operating), or achievements to differ from the future results, performance (financial or operating), or achievements expressed or implied by such forward-looking statements. The above factors are more fully discussed in the company's SEC filings.

(TABLE FOLLOWS)

Contact:BAB, Inc.
Michael K. Murtaugh (847) 948-7520
Fax: (847) 405-8140
www.babcorp.com
BAB, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Quarter Ended Nine Months Ended
08/31/24 08/31/23 % Change 08/31/24 08/31/23 % Change
REVENUES
Royalty fees from franchised stores$519,299 $515,970 0.6% $1,492,463 $1,453,511 2.7%
Franchise and area development fee revenue 9,298 11,306 -17.8% 28,759 22,707 26.7%
Licensing fees and other income 49,869 63,889 -21.9% 209,969 199,883 5.0%
Marketing Fund Revenue 293,469 345,486 -15.1% 859,516 870,543 -1.3%
Total Revenue 871,935 936,651 -6.9% 2,590,707 2,546,644 1.7%
OPERATING COSTS AND EXPENSES
Selling, general and administrative 372,561 371,380 0.3% 1,211,895 1,233,982 -1.8%
Depreciation and amortization 981 981 0.0% 5,942 2,826 110.3%
Marketing Fund Expenses 293,469 345,486 -15.1% 859,516 870,543 -1.3%
Total Expense 667,011 717,847 -7.1% 2,077,353 2,107,351 -1.4%
Income from operations 204,924 218,804 -6.3% 513,354 439,293 16.9%
Interest/other income 17,903 15,054 18.9% 50,164 20,613 143.4%
Income taxes (62,500) (66,100) -5.4% (159,000) (130,300) 22.0%
NET INCOME$160,327 $167,758 -4.4% $404,518 $329,606 22.7%
Earnings per share - basic and diluted$0.02 $0.02 N/M $0.06 $0.05 N/M
Average number of shares outstanding 7,263,508 7,263,508 7,263,508 7,263,508

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.